These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 16088233)

  • 1. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients.
    Ferretti G; Fabi A; Carlini P; Papaldo P; Cordiali Fei P; Di Cosimo S; Salesi N; Giannarelli D; Alimonti A; Di Cocco B; D'Agosto G; Bordignon V; Trento E; Cognetti F
    Oncology; 2005; 69(1):35-43. PubMed ID: 16088233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients.
    Santini D; Vincenzi B; Galluzzo S; Battistoni F; Rocci L; Venditti O; Schiavon G; Angeletti S; Uzzalli F; Caraglia M; Dicuonzo G; Tonini G
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4482-6. PubMed ID: 17671133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients.
    Santini D; Vincenzi B; Dicuonzo G; Avvisati G; Massacesi C; Battistoni F; Gavasci M; Rocci L; Tirindelli MC; Altomare V; Tocchini M; Bonsignori M; Tonini G
    Clin Cancer Res; 2003 Aug; 9(8):2893-7. PubMed ID: 12912933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases.
    Leto G; Badalamenti G; Arcara C; Crescimanno M; Flandina C; Tumminello FM; Incorvaia L; Gebbia N; Fulfaro F
    Anticancer Res; 2006; 26(1A):23-6. PubMed ID: 16475674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic effects of surgery: quantitative analysis of circulating basic fibroblast growth factor (bFGF), Vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-beta) in patients with breast cancer who underwent limited or extended surgery.
    Curigliano G; Petit JY; Bertolini F; Colleoni M; Peruzzotti G; de Braud F; Gandini S; Giraldo A; Martella S; Orlando L; Munzone E; Pietri E; Luini A; Goldhirsch A
    Breast Cancer Res Treat; 2005 Sep; 93(1):35-40. PubMed ID: 16184456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6.
    Dicuonzo G; Vincenzi B; Santini D; Avvisati G; Rocci L; Battistoni F; Gavasci M; Borzomati D; Coppola R; Tonini G
    J Interferon Cytokine Res; 2003 Nov; 23(11):649-54. PubMed ID: 14651779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating angiogenic cytokines in multiple myeloma and related disorders.
    Urba ska-Rys H; Wierzbowska A; Robak T
    Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
    Dosquet C; Coudert MC; Lepage E; Cabane J; Richard F
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelial growth factor activity after switching of bisphosphonate treatment for metastatic breast cancer.
    Amir E; Trinkaus M; Simmons CE; Dranitsaris G; Clemons MJ
    J Clin Pathol; 2009 May; 62(5):474-6. PubMed ID: 19398598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients.
    Santini D; Vincenzi B; Avvisati G; Dicuonzo G; Battistoni F; Gavasci M; Salerno A; Denaro V; Tonini G
    Clin Cancer Res; 2002 May; 8(5):1080-4. PubMed ID: 12006522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients.
    Vincenzi B; Santini D; Dicuonzo G; Battistoni F; Gavasci M; La Cesa A; Grilli C; Virzì V; Gasparro S; Rocci L; Tonini G
    J Interferon Cytokine Res; 2005 Mar; 25(3):144-51. PubMed ID: 15767788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance.
    Zhao X; Xu X; Guo L; Ragaz J; Guo H; Wu J; Shao Z; Zhu J; Guo X; Chen J; Zhu B; Wang Z; Hu X
    Breast Cancer Res Treat; 2010 Dec; 124(3):733-43. PubMed ID: 20882405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases.
    Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E
    Med Oncol; 2008; 25(3):346-9. PubMed ID: 18204821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring serum levels ELR+ CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma.
    Pappa CA; Tsirakis G; Kanellou P; Kaparou M; Stratinaki M; Xekalou A; Alegakis A; Boula A; Stathopoulos EN; Alexandrakis MG
    Cytokine; 2011 Dec; 56(3):616-20. PubMed ID: 21940178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology.
    Keyes KA; Mann L; Cox K; Treadway P; Iversen P; Chen YF; Teicher BA
    Cancer Chemother Pharmacol; 2003 Apr; 51(4):321-7. PubMed ID: 12721760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity.
    Robak E; Woźniacka A; Sysa-Jedrzejowska A; Stepień H; Robak T
    Eur Cytokine Netw; 2001; 12(3):445-52. PubMed ID: 11566625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone-related growth factors and zoledronic acid regulate the PTHrP/PTH.1 receptor bioregulation systems in MG-63 human osteosarcoma cells.
    Tenta R; Sourla A; Lembessis P; Koutsilieris M
    Anticancer Res; 2006; 26(1A):283-91. PubMed ID: 16475708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Plasma level and prognostic significance of VEGF, bFGF and MMP-9 in patients with advanced non-small-cell lung cancer].
    Zhao J; Liu XY; Zhang QY; Jiang W
    Zhonghua Zhong Liu Za Zhi; 2005 Nov; 27(11):676-9. PubMed ID: 16438890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
    Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
    Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer].
    Tang JH; Zhao JH; Gong JP; Qin JW; Pan LQ; Xu ZY
    Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):210-4. PubMed ID: 17649639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.